Recognize
High tumor burden, rapidly proliferative or treatment-sensitive malignancy, high LDH, renal dysfunction and elevated baseline urate increase risk; spontaneous TLS can occur.
Hyperkalemia, hyperphosphatemia, hypocalcemia and AKI around cancer therapy.
High tumor burden, rapidly proliferative or treatment-sensitive malignancy, high LDH, renal dysfunction and elevated baseline urate increase risk; spontaneous TLS can occur.
High-risk patients need frequent laboratory reassessment and cardiac monitoring because hyperkalemia and hypocalcemia-related arrhythmias may evolve rapidly.
Reassess trajectory, organ support, competing diagnoses and failure of first-line therapy; escalate early when physiology is worsening.
Evidence status
Review metadata not yet recorded.
Status, review dates and guideline versions appear here once editorial metadata is authored for this content.